title: Computational analysis and predictive modeling of polymorph descriptors.
abstract: BACKGROUND
  A computation approach based on integrating high throughput binding affinity comparison and binding descriptor classifications was utilized to establish the correlation among substrate properties and their affinity to Breast Cancer Resistant Protein (BCRP). The uptake rates of Mitoxantrone in the presence of various substrates were evaluated as an in vitro screening index for comparison of their binding affinity to BCRP.The effects of chemical properties of various chemotherapeutics, such as antiviral, antibiotic, calcium channel blockers, anticancer and antifungal agents, on their affinity to BCRP, were evaluated using HEK (human embryonic kidney) cells in which 3 polymorphs, namely 482R (wild type) and two mutants (482G and 482T) of BCRP, have been identified. The quantitative structure activity relationship (QSAR) model was developed using the sequential approaches of Austin Model 1 (AM1), CODESSA program, heuristic method (HM) and multiple linear regression (MLR) to establish the relationship between structural specificity of BCRP substrates and their uptake rates by BCRP polymorphs.
  
  
  RESULTS
  The BCRP mutations may induce conformational changes as manifested by the altered uptake rates of Mitoxantrone by BCRP in the presence of other competitive binding substrates that have a varying degree of affinities toward BCRP efflux. This study also revealed that the binding affinity of test substrates to each polymorph was affected by varying descriptors, such as constitutional, topological, geometrical, electrostatic, thermodynamic, and quantum chemical descriptors.
  
  
  CONCLUSIONS
  Descriptors involved with the net surface charge and energy level of substrates seem to be the common integral factors for defining binding specificity of selected substrates to BCRP polymorph. The reproducible outcomes and validation process further supported the accuracy of the computational model in assessing the correlation among descriptors involved with substrate affinity to BCRP polymorph. A quantitative computation approach will provide important structural insight into optimal designing of new chemotherapeutic agents with improved pharmacological efficacies.
authors: Division of Pharmaceutical Sciences, College of Pharmacy, University of Missouri-Kansas City, Missouri, MO 64108, USA. Leech@umkc.edu.
authors: Yugyung
authors: Y
authors: Lee
authors: Sourav
authors: S
authors: Jana
authors: Gayathri
authors: G
authors: Acharya
authors: Chi H
authors: CH
authors: Lee
references: Nat Rev Drug Discov. 2006 Sep;5(9):730-9
references: 16888652
references: Biomaterials. 2010 Jan;31(3):552-8
references: 19857895
references: Chem Rev. 2010 Oct 13;110(10):5714-89
references: 20731377
references: Clin Pharmacokinet. 2003;42(1):59-98
references: 12489979
references: Pharm Res. 2003 Feb;20(2):161-8
references: 12636153
references: Respir Res. 2005 Jun 20;6:59
references: 15967026
references: J Biol Chem. 1991 Oct 15;266(29):19858-64
references: 1918089
references: Brief Bioinform. 2006 Dec;7(4):339-53
references: 17116646
references: J Pharmacol Exp Ther. 2001 Jun;297(3):1137-43
references: 11356939
references: Digestion. 2006;74(2):101-8
references: 17159348
references: PLoS Comput Biol. 2010 Sep 23;6(9):e1000938
references: 20957118
references: Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2355-60
references: 20133880
references: J Pharmacol Exp Ther. 2007 Oct;323(1):19-30
references: 17616561
references: J Antimicrob Chemother. 2007 Feb;59(2):238-45
references: 17202245
references: Biochem Biophys Res Commun. 1991 Mar 29;175(3):880-5
references: 1673839
references: Drug Metab Dispos. 2007 Apr;35(4):623-32
references: 17237154
references: Drug Metab Pharmacokinet. 2003;18(3):194-202
references: 15618735
references: Cancer Res. 2012 Nov 1;72(21):5588-99
references: 23118055
references: Trends Pharmacol Sci. 2009 Sep;30(9):470-4
references: 19717193
references: Biochim Biophys Acta. 2001 Jun 6;1512(2):171-82
references: 11406094
references: Pharm Res. 2008 Jun;25(6):1244-55
references: 18202831
references: Nat Rev Drug Discov. 2010 Mar;9(3):215-36
references: 20190787
references: Mol Pharmacol. 2009 Nov;76(5):946-56
references: 19633067
references: Mol Cancer Ther. 2002 Apr;1(6):417-25
references: 12477054
references: Mol Cancer Ther. 2006 Oct;5(10):2459-67
references: 17041089
references: Pharmacogenomics J. 2002;2(3):191-6
references: 12082591
references: Mol Pharm. 2004 Jul-Aug;1(4):290-9
references: 15981588
references: Pharm Res. 2010 May;27(5):739-49
references: 20221898
references: Biochem J. 2003 Aug 1;373(Pt 3):767-74
references: 12741957
references: J Pharm Sci. 2007 Dec;96(12):3226-35
references: 17518356
references: J Bioenerg Biomembr. 2001 Dec;33(6):503-11
references: 11804192
references: Cell Immunol. 2006 Dec;244(2):121-4
references: 17434155
references: Sci Signal. 2009 Dec 08;2(100):re9
references: 19996458
references: Cancer Res. 2010 Sep 1;70(17):6704-14
references: 20643779
references: Curr Opin Chem Biol. 2010 Aug;14(4):467-74
references: 20663707
references: Anal Biochem. 2010 Jun 1;401(1):148-53
references: 20206116
references: Eur J Clin Pharmacol. 2005 Jul;61(5-6):389-94
references: 15912392
references: Int J Cancer. 2008 Oct 1;123(7):1712-20
references: 18623116
references: Nat Biotechnol. 2005 Jun;23(6):639
references: 15940222
references: J Cell Sci. 2000 Jun;113 ( Pt 11):2011-21
references: 10806112
references: Phytother Res. 2002 May;16(3):232-5
references: 12164267
references: Drug Metab Dispos. 2010 May;38(5):740-4
references: 20159988
references: Pharmacol Rev. 2003 Sep;55(3):425-61
references: 12869659
references: J Chem Inf Model. 2008 Oct;48(10):2081-94
references: 18826208
references: Pharm Res. 2004 Oct;21(10):1895-903
references: 15553238
references: Dent Mater. 2005 Jul;21(7):591-8
references: 15978267
references: Br J Pharmacol. 2012 Jul;166(6):1846-59
references: 22324512
references: Mol Cancer Ther. 2003 Jan;2(1):105-12
references: 12533678
references: Pharm Res. 2009 Aug;26(8):1816-31
references: 19421845
references: Mol Cancer Ther. 2002 Apr;1(6):427-34
references: 12477055
references: Carcinogenesis. 2007 Aug;28(8):1740-4
references: 17494054
references: PLoS Comput Biol. 2011 Apr;7(4):e1002037
references: 21552547
references: Gene. 1997 Jan 31;185(1):77-85
references: 9034316
references: Annu Rev Biophys Biomol Struct. 2007;36:21-42
references: 17201676
references: Chem Pharm Bull (Tokyo). 1980 Jan;28(1):245-54
references: 6988091
references: Adv Drug Deliv Rev. 2003 Jan 21;55(1):3-29
references: 12535572